|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9233112||LUPIN LTD||Pharmaceutical compositions of cefixime|| |
(5 years from now)
Suprax is owned by Lupin Ltd.
Suprax contains Cefixime.
Suprax has a total of 1 drug patent out of which 0 drug patents have expired.
Suprax was authorised for market use on 20 February, 2013.
Suprax is available in for suspension;oral dosage forms.
Suprax can be used as methods for treating bacterial infections.
The generics of Suprax are possible to be released after 14 December, 2028.
Market Authorisation Date: 20 February, 2013
Treatment: Methods for treating bacterial infections
Dosage: FOR SUSPENSION;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic